Journal of Vascular and Interventional Radiology最新文献

英文中文

Pulmonary Arteriovenous Malformation Embolization: The Role of Contrast-Enhanced CT and Standardized Outcome Measures 肺动静脉畸形栓塞：对比增强计算机断层扫描和标准化结果测量的作用。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-03-01 Epub Date: 2025-09-20 DOI: 10.1016/j.jvir.2025.09.024

Daniel A.F. van den Heuvel MD , Sjors Klompmaker MD, MS, PhD , Josefien Hessels MD , Arjen D. Diederik MD , Johannes J. Mager MD, PhD , Jos C. van den Berg MD, PhD , Marco C. Post MD, PhD

Purpose

To determine the pulmonary arteriovenous malformation (PAVM) persistence rate in patients treated with microcoils, vascular plugs, or a combination of these and to propose standardized outcome criteria using contrast-enhanced computed tomography (CT).

Materials and Methods

This retrospective study included all adult patients undergoing embolization of de novo PAVMs using microcoils and/or Type I Amplatzer vascular plugs (AVP), between 2005 and 2012. PAVM persistence was assessed at 6 months using contrast-enhanced CT, focusing on vein enhancement vs shrinkage rates. Endpoints were overall persistence and persistence in technically successful treated de novo PAVMs. This was defined as confirmed occlusion of all embolized feeding arteries, embolization of ≤10 mm of the sac, and without missed feeding arteries.

Results

The study included 113 patients (mean age, 42 years [SD ± 18]; 63 women), representing 292 PAVMs for analysis. Persistence was observed in 82 of 292 (28%) PAVMs and was angiographically confirmed in all cases. Of the persistent PAVMs, 16% showed >70% sac shrinkage on contrast-enhanced CT. Among 108 technically successful treated simple PAVMs, overall persistence was 11% (7% for Type I AVP and 21% for coils).

Conclusions

Based on contrast-enhanced CT and with angiographical confirmation, overall PAVM persistence at 6 months after embolization with coils or AVPs was 28%. A suspected high sensitivity of contrast-enhanced CT for detecting PAVM persistence may partially account for outcome differences compared with those reported in previous studies and underscores the need for standardized imaging and reporting protocols.

目的：确定接受微线圈、血管塞或两者联合治疗的患者的肺动静脉畸形（PAVM）持续率，并使用对比增强计算机断层扫描（CECT）提出标准化的结果标准。材料和方法：本回顾性研究纳入了2005年至2012年间使用微线圈和/或Amplatzer I型血管塞（AVP-I）栓塞新生pavm的所有成年患者。在6个月时使用CECT评估PAVM持续性，重点是静脉增强和收缩率。终点是总体持久性和技术上成功治疗的新发pavm的持久性。这被定义为确认所有栓塞的供血动脉闭塞，栓塞≤10毫米囊，没有遗漏的供血动脉。结果：研究纳入113例患者（平均年龄42±18岁，女性63例），共292例pavm进行分析。292例pavm中有82例（28%）存在持续性，所有病例均经血管造影证实。在持续性pavm中，16%在CECT上显示bbb70 %的囊缩小。在108例技术上成功治疗的单纯pavm中，总体持久性为11% （AVP-I组为7%，线圈组为21%）。结论：基于CECT和血管造影证实，在线圈或avp栓塞后6个月，PAVM的总体持久性为28%。与之前的研究相比，CECT检测PAVM持久性的高灵敏度可能部分解释了结果差异，并强调了标准化成像和报告协议的必要性。

{"title":"Pulmonary Arteriovenous Malformation Embolization: The Role of Contrast-Enhanced CT and Standardized Outcome Measures","authors":"Daniel A.F. van den Heuvel MD , Sjors Klompmaker MD, MS, PhD , Josefien Hessels MD , Arjen D. Diederik MD , Johannes J. Mager MD, PhD , Jos C. van den Berg MD, PhD , Marco C. Post MD, PhD","doi":"10.1016/j.jvir.2025.09.024","DOIUrl":"10.1016/j.jvir.2025.09.024","url":null,"abstract":"<div><h3>Purpose</h3><div>To determine the pulmonary arteriovenous malformation (PAVM) persistence rate in patients treated with microcoils, vascular plugs, or a combination of these and to propose standardized outcome criteria using contrast-enhanced computed tomography (CT).</div></div><div><h3>Materials and Methods</h3><div>This retrospective study included all adult patients undergoing embolization of de novo PAVMs using microcoils and/or Type I Amplatzer vascular plugs (AVP), between 2005 and 2012. PAVM persistence was assessed at 6 months using contrast-enhanced CT, focusing on vein enhancement vs shrinkage rates. Endpoints were overall persistence and persistence in technically successful treated de novo PAVMs. This was defined as confirmed occlusion of all embolized feeding arteries, embolization of ≤10 mm of the sac, and without missed feeding arteries.</div></div><div><h3>Results</h3><div>The study included 113 patients (mean age, 42 years [SD ± 18]; 63 women), representing 292 PAVMs for analysis. Persistence was observed in 82 of 292 (28%) PAVMs and was angiographically confirmed in all cases. Of the persistent PAVMs, 16% showed >70% sac shrinkage on contrast-enhanced CT. Among 108 technically successful treated simple PAVMs, overall persistence was 11% (7% for Type I AVP and 21% for coils).</div></div><div><h3>Conclusions</h3><div>Based on contrast-enhanced CT and with angiographical confirmation, overall PAVM persistence at 6 months after embolization with coils or AVPs was 28%. A suspected high sensitivity of contrast-enhanced CT for detecting PAVM persistence may partially account for outcome differences compared with those reported in previous studies and underscores the need for standardized imaging and reporting protocols.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 3","pages":"Article 107853"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145126374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of Ketamine Sedation for Interventional Radiology Procedures: Experience in 900 Consecutive Patients 介入放射治疗中氯胺酮镇静的安全性：900例连续患者的经验。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-03-01 Epub Date: 2025-12-19 DOI: 10.1016/j.jvir.2025.107970

Maanasa Bommineni BS , Martin Nguyen BS , Ashraf Ahmad MD , Adam M. Belcher PhD , Michael Korona MD , Amy R. Deipolyi MD, PhD

Purpose

To evaluate the safety of ketamine/midazolam sedation for interventional radiology (IR) procedures administered by IR physicians without anesthesiology personnel present.

Materials and Methods

This single-center retrospective study, approved by the institutional review board (IRB) with waiver of consent, included all 900 consecutive IR procedures performed in adults with intravenous ketamine/midazolam sedation (July 2024 to January 2025). Demographic data, procedure type, medication doses, and adverse events were extracted from the electronic medical record (Cerner Millennium; Oracle Health, Kansas City, Missouri). All adverse events within 30 days were identified. Sedation-related adverse events were defined as administration of reversal agents, activation of a rapid response or code team, allergic reaction, hypotension requiring vasopressors, or respiratory events (intubation or placement of an advanced airway) within 6 hours of the procedure.

Results

Procedures included biopsies (40%), drainages (38%), venous access (15%), angiography/embolization (5%), and others (2%). Median midazolam and ketamine doses were 2 mg (range, 0.5–6 mg) and 40 mg (range, 20–260 mg), respectively. Mean lowest oxygen saturation was 96% (range, 83%–100%); desaturation <90% occurred in 6 cases (0.7%). No patient required intubation, advanced airway placement, or vasopressor support. Four sedation-related adverse events (0.4%) occurred: hypotension treated with flumazenil, combativeness, patient fall, and transient desaturation while prone. Thirty-three nonsedation–related adverse events (3.7%) occurred within 30 days.

Conclusions

Ketamine/midazolam sedation was safely performed across a broad range of IR procedures. Adverse respiratory and hemodynamic events were rare, supporting ketamine/midazolam as a safe alternative to fentanyl/midazolam sedation in IR practice.

目的：评价氯胺酮/咪达唑仑镇静在没有麻醉人员在场的情况下由IR医师实施的介入放射（IR）手术中的安全性。材料和方法：这项由机构审查委员会批准的单中心回顾性研究，包括所有900例静脉注射氯胺酮/咪达唑仑镇静的成人连续IR手术（2024年7月至2025年1月）。从电子病历（Cerner Millennium, Oracle Health, Kansas City， MO）中提取人口统计数据、手术类型、药物剂量和不良事件。在30天内确定所有不良事件。镇静相关不良事件被定义为在手术后6小时内使用逆转药物、激活快速反应或编码小组、过敏反应、需要使用血管加压药物的低血压、或呼吸事件（插管或放置先进气道）。结果：手术包括活组织检查（40%）、引流（38%）、静脉通路（15%）、血管造影/栓塞（5%）和其他（2%）。中位咪达唑仑和氯胺酮剂量分别为2毫克（范围：0.5-6毫克）和40毫克（范围：20-260毫克）。平均最低血氧饱和度96%（范围83 ~ 100%）；结论：氯胺酮/咪达唑仑镇静在广泛的IR手术中是安全的。不良呼吸和血流动力学事件罕见，支持氯胺酮/咪达唑仑在IR实践中作为芬太尼/咪达唑仑镇静的安全替代品。

{"title":"Safety of Ketamine Sedation for Interventional Radiology Procedures: Experience in 900 Consecutive Patients","authors":"Maanasa Bommineni BS , Martin Nguyen BS , Ashraf Ahmad MD , Adam M. Belcher PhD , Michael Korona MD , Amy R. Deipolyi MD, PhD","doi":"10.1016/j.jvir.2025.107970","DOIUrl":"10.1016/j.jvir.2025.107970","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the safety of ketamine/midazolam sedation for interventional radiology (IR) procedures administered by IR physicians without anesthesiology personnel present.</div></div><div><h3>Materials and Methods</h3><div>This single-center retrospective study, approved by the institutional review board (IRB) with waiver of consent, included all 900 consecutive IR procedures performed in adults with intravenous ketamine/midazolam sedation (July 2024 to January 2025). Demographic data, procedure type, medication doses, and adverse events were extracted from the electronic medical record (Cerner Millennium; Oracle Health, Kansas City, Missouri). All adverse events within 30 days were identified. Sedation-related adverse events were defined as administration of reversal agents, activation of a rapid response or code team, allergic reaction, hypotension requiring vasopressors, or respiratory events (intubation or placement of an advanced airway) within 6 hours of the procedure.</div></div><div><h3>Results</h3><div>Procedures included biopsies (40%), drainages (38%), venous access (15%), angiography/embolization (5%), and others (2%). Median midazolam and ketamine doses were 2 mg (range, 0.5–6 mg) and 40 mg (range, 20–260 mg), respectively. Mean lowest oxygen saturation was 96% (range, 83%–100%); desaturation <90% occurred in 6 cases (0.7%). No patient required intubation, advanced airway placement, or vasopressor support. Four sedation-related adverse events (0.4%) occurred: hypotension treated with flumazenil, combativeness, patient fall, and transient desaturation while prone. Thirty-three nonsedation–related adverse events (3.7%) occurred within 30 days.</div></div><div><h3>Conclusions</h3><div>Ketamine/midazolam sedation was safely performed across a broad range of IR procedures. Adverse respiratory and hemodynamic events were rare, supporting ketamine/midazolam as a safe alternative to fentanyl/midazolam sedation in IR practice.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 3","pages":"Article 107970"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145805920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk-Stratified Timing of Thoracic Endovascular Aortic Repair for Complicated Type B Aortic Dissection with Acute Limb Ischemia TEVAR治疗合并急性肢体缺血的B型主动脉夹层的风险分层时机。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-03-01 Epub Date: 2025-12-19 DOI: 10.1016/j.jvir.2025.107971

Lei Zhang MD , Dexiang Xia MD , Rui Li MD , Xin Li MD, PhD , Chang Shu MD, PhD

Purpose

To evaluate a Rutherford classification–based protocol for determining the timing of thoracic endovascular aortic repair (TEVAR) in patients with complicated Type B aortic dissection (coTBAD) and acute limb ischemia (ALI) and to assess the effectiveness of a TEVAR-first revascularization approach.

Materials and Methods

From October 2016 to February 2020, 33 consecutive patients with coTBAD and ALI were included in this retrospective study. Based on intervention timing, patients were classified into an ultraearly group (TEVAR within 24 hours of admission, n = 20) and an early group (TEVAR after 24 hours; median, 48 hours; n = 13). Demographics, in-hospital mortality, complications, and limb revascularization outcomes were compared.

Results

Overall in-hospital mortality was 9.1% (3/33), with all fatalities in the ultraearly group (15.0%, 3/20) and none in the early group (0/13, P = .261). This outcome is consistent with the significantly more severe Rutherford classification in the ultraearly group (all IIb/III) than in the early group (all I/IIa, P < .001). TEVAR as first-line treatment successfully achieved limb revascularization in 93.9% (31/33) of cases. Only 2 ultraearly group patients required additional revascularization. During a median 82-month follow-up, 2 nonaortic deaths occurred (1 per group), and the sole amputation was in the ultraearly group.

Conclusions

This single-center study demonstrates that a TEVAR-first strategy was highly effective, achieving successful limb reperfusion in the vast majority of patients. A risk-adapted strategy, utilizing ultraearly (≤24 hours) or early (within 72 hours) TEVAR based on Rutherford classification, was feasible and associated with acceptable overall outcomes.

目的：评价一种基于Rutherford分类的方案，用于确定合并B型主动脉夹层（coTBAD）和急性肢体缺血（ALI）患者进行胸椎血管内主动脉修复（TEVAR）的时机，并评估TEVAR-first血运重建术的疗效。材料与方法：2016年10月至2020年2月，连续33例coTBAD和ALI患者纳入回顾性研究。根据干预时间将患者分为超早期组（入院24小时内TEVAR， n=20）和早期组（入院24小时后TEVAR，中位48小时，n=13）。比较了人口统计学、住院死亡率、并发症和肢体血运重建结果。结果：住院总死亡率为9.1%(3/33)，超早期组全部死亡（15.0%,3/20），早期组无死亡（0/13，P=0.261）。这一结果与超早期组（全部为IIb/III）比早期组（全部为I/IIa； p）明显更严重的卢瑟福分类是一致的。结论：本单中心研究表明tevar优先策略是非常有效的，绝大多数患者成功实现了肢体再灌注。采用基于卢瑟福分类的超早期（≤24小时）或早期（72小时内）TEVAR的风险适应策略是可行的，并且与可接受的总体结果相关。

{"title":"Risk-Stratified Timing of Thoracic Endovascular Aortic Repair for Complicated Type B Aortic Dissection with Acute Limb Ischemia","authors":"Lei Zhang MD , Dexiang Xia MD , Rui Li MD , Xin Li MD, PhD , Chang Shu MD, PhD","doi":"10.1016/j.jvir.2025.107971","DOIUrl":"10.1016/j.jvir.2025.107971","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate a Rutherford classification–based protocol for determining the timing of thoracic endovascular aortic repair (TEVAR) in patients with complicated Type B aortic dissection (coTBAD) and acute limb ischemia (ALI) and to assess the effectiveness of a TEVAR-first revascularization approach.</div></div><div><h3>Materials and Methods</h3><div>From October 2016 to February 2020, 33 consecutive patients with coTBAD and ALI were included in this retrospective study. Based on intervention timing, patients were classified into an ultraearly group (TEVAR within 24 hours of admission, n = 20) and an early group (TEVAR after 24 hours; median, 48 hours; n = 13). Demographics, in-hospital mortality, complications, and limb revascularization outcomes were compared.</div></div><div><h3>Results</h3><div>Overall in-hospital mortality was 9.1% (3/33), with all fatalities in the ultraearly group (15.0%, 3/20) and none in the early group (0/13, <em>P</em> = .261). This outcome is consistent with the significantly more severe Rutherford classification in the ultraearly group (all IIb/III) than in the early group (all I/IIa, <em>P</em> < .001). TEVAR as first-line treatment successfully achieved limb revascularization in 93.9% (31/33) of cases. Only 2 ultraearly group patients required additional revascularization. During a median 82-month follow-up, 2 nonaortic deaths occurred (1 per group), and the sole amputation was in the ultraearly group.</div></div><div><h3>Conclusions</h3><div>This single-center study demonstrates that a TEVAR-first strategy was highly effective, achieving successful limb reperfusion in the vast majority of patients. A risk-adapted strategy, utilizing ultraearly (≤24 hours) or early (within 72 hours) TEVAR based on Rutherford classification, was feasible and associated with acceptable overall outcomes.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 3","pages":"Article 107971"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145805497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

On the Use of Transvenous Obliteration for the Primary Prophylaxis of Gastric Varices 经静脉闭塞术在胃静脉曲张初级预防中的应用。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-03-01 Epub Date: 2025-12-04 DOI: 10.1016/j.jvir.2025.107946

Ron C. Gaba MD, MS , Juan-Carlos García-Pagán MD, PhD

引用次数: 0

2025 Dotter Lecture: Innovating Innovation—Building on Dotter’s Legacy 2025波特讲座：创新创新：以波特的遗产为基础。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-03-01 Epub Date: 2025-11-24 DOI: 10.1016/j.jvir.2025.107923

Lindsay Machan MD, O.C.

引用次数: 0

Systematic Literature Review and Meta-analysis of the Cardiovascular Effects of Transjugular Intrahepatic Portosystemic Shunt Creation for Decompensated Liver Cirrhosis 经颈静脉肝内门静脉系统分流术治疗失代偿期肝硬化的心血管效应的系统文献综述和meta分析。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-03-01 Epub Date: 2025-11-24 DOI: 10.1016/j.jvir.2025.107924

Wali Badar MD , Ramzy C. Khabbaz MD, MS , Arinze Ekowa BS , Sarah Shalaby MD, PhD , Anna Baiges MD, PhD , Juan-Carlos García-Pagán MD, PhD , Ron C. Gaba MD, MS

Purpose

To characterize the cardiovascular (CV) effects of transjugular intrahepatic portosystemic shunt (TIPS) creation through systematic literature review and meta-analysis.

Materials and Methods

A systematic literature review was performed from 1990 to 2025. The search strategy included key words for TIPS creation, cardiac-related terms (eg, heart, CV, mitral, atrial, and ventricular), and clinical outcomes (eg, survival, mortality, and decompensation). Eligible articles were English language studies with >5 patients reporting CV outcomes after TIPS creation. Outcome measures included hemodynamic changes, CV index alterations, CV decompensation, and mortality. Data were aggregated, and pooled estimated effects were reported.

Results

Thirty-two articles with 4,452 patients were included. Right atrial pressure (RAP) (+5.2 mm Hg; 95% CI, 4.0–6.2; P < .001), cardiac output (CO) (+1.9 L/min; 95% CI, 1.3–2.7; P < .001), cardiac index (CI) (+1.0 L/min/m²; 95% CI, 0.6–1.4; P < .001), pulmonary artery pressure (PAP) (+8.6 mm Hg; 95% CI, 4.1–13.1; P = .006), pulmonary capillary wedge pressure (PCWP) (5.7 mm Hg; 95% CI, 2.1–9.3; P = .010), and E/A ratio (+0.2; 95% CI, 0.1–0.4; P = .016) significantly increased immediately after TIPS creation. RAP and E/A ratio returned to baseline 1–6 months after TIPS creation, whereas CO, CI, PAP, and PCWP did not. The pooled incidence of post-TIPS cardiac decompensation was 9% (95% CI, 4%–21%). One-year cardiac mortality rate was 3% (95% CI, 2%–5%). Diastolic dysfunction was associated with increased 1-year post-TIPS mortality (odds ratio, 2.26; 95% CI, 1.43–3.59; P = .001).

Conclusions

Transient CV changes and cardiac decompensation can occur after TIPS creation. Diastolic dysfunction may predict cardiac mortality.

目的：通过系统的文献回顾和荟萃分析，探讨经颈静脉肝内门静脉系统分流术（TIPS）的心血管（CV）效应。材料和方法：对1990-2025年的文献进行系统回顾。搜索策略包括经颈静脉肝内门静脉系统分流术、心脏相关术语（如心脏、心血管、二尖瓣、心房、心室）和临床结果（如生存、死亡率、失代偿）的关键词。符合条件的文章是5篇报告TIPS后CV结果的英语研究。结果测量包括血流动力学改变、心血管指数改变、心血管失代偿和死亡率。汇总数据并汇总估计效果。结果：纳入32篇文章，4452例患者。右房压（RAP）（+5.2 mmHg, 95% CI:4.0-6.2; P2, 95% CI:0.6-1.4; p）结论：TIPS后可发生一过性CV改变和心脏失代偿。舒张功能障碍可预测心脏死亡率。

{"title":"Systematic Literature Review and Meta-analysis of the Cardiovascular Effects of Transjugular Intrahepatic Portosystemic Shunt Creation for Decompensated Liver Cirrhosis","authors":"Wali Badar MD , Ramzy C. Khabbaz MD, MS , Arinze Ekowa BS , Sarah Shalaby MD, PhD , Anna Baiges MD, PhD , Juan-Carlos García-Pagán MD, PhD , Ron C. Gaba MD, MS","doi":"10.1016/j.jvir.2025.107924","DOIUrl":"10.1016/j.jvir.2025.107924","url":null,"abstract":"<div><h3>Purpose</h3><div>To characterize the cardiovascular (CV) effects of transjugular intrahepatic portosystemic shunt (TIPS) creation through systematic literature review and meta-analysis.</div></div><div><h3>Materials and Methods</h3><div>A systematic literature review was performed from 1990 to 2025. The search strategy included key words for TIPS creation, cardiac-related terms (eg, heart, CV, mitral, atrial, and ventricular), and clinical outcomes (eg, survival, mortality, and decompensation). Eligible articles were English language studies with >5 patients reporting CV outcomes after TIPS creation. Outcome measures included hemodynamic changes, CV index alterations, CV decompensation, and mortality. Data were aggregated, and pooled estimated effects were reported.</div></div><div><h3>Results</h3><div>Thirty-two articles with 4,452 patients were included. Right atrial pressure (RAP) (+5.2 mm Hg; 95% CI, 4.0–6.2; <em>P</em> < .001), cardiac output (CO) (+1.9 L/min; 95% CI, 1.3–2.7; <em>P</em> < .001), cardiac index (CI) (+1.0 L/min/m<sup>2</sup>; 95% CI, 0.6–1.4; <em>P</em> < .001), pulmonary artery pressure (PAP) (+8.6 mm Hg; 95% CI, 4.1–13.1; <em>P</em> = .006), pulmonary capillary wedge pressure (PCWP) (5.7 mm Hg; 95% CI, 2.1–9.3; <em>P</em> = .010), and E/A ratio (+0.2; 95% CI, 0.1–0.4; <em>P</em> = .016) significantly increased immediately after TIPS creation. RAP and E/A ratio returned to baseline 1–6 months after TIPS creation, whereas CO, CI, PAP, and PCWP did not. The pooled incidence of post-TIPS cardiac decompensation was 9% (95% CI, 4%–21%). One-year cardiac mortality rate was 3% (95% CI, 2%–5%). Diastolic dysfunction was associated with increased 1-year post-TIPS mortality (odds ratio, 2.26; 95% CI, 1.43–3.59; <em>P</em> = .001).</div></div><div><h3>Conclusions</h3><div>Transient CV changes and cardiac decompensation can occur after TIPS creation. Diastolic dysfunction may predict cardiac mortality.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 3","pages":"Article 107924"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Endovascular Intervention in Combination with Medical Therapy versus Medical Therapy Alone in the Initial Management of Patients with Primary Budd-Chiari Syndrome: A Randomized Controlled Trial 早期血管内干预联合药物治疗与单纯药物治疗对原发性布-恰里综合征患者的初始治疗：一项随机对照试验

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-03-01 Epub Date: 2025-12-18 DOI: 10.1016/j.jvir.2025.107967

Sagnik Biswas MD, DM , Shekhar Swaroop MD, DM , Shubham Mehta MD, DM , Arnav Aggarwal MD, DM , Sarthak Saxena MD , Samagra Agarwal MD, DM , Deepak Gunjan MD, DM , Shivanand Gamanagatti MD , Shalimar MD, DM

Purpose

To compare the clinical outcomes between standard medical therapy (SMT) and early endovascular intervention as the first step of management in primary Budd-Chiari syndrome (BCS).

Materials and Methods

Symptomatic patients with primary BCS having either hepatic vein (HV) obstruction (Type II) or combined obstruction of HV and inferior vena cava (Type III) were enrolled. Twenty-three patients were randomized to receive SMT for 12 weeks, whereas 21 received early endovascular intervention with SMT. Primary outcome was complete response (CR) at 12 weeks: resolution of ascites, normalization of serum bilirubin, prevention of first episode of variceal bleeding or its recurrence, and absence of spontaneous bacterial peritonitis. Adverse events (AEs) were reported as per the Society of Interventional Radiology (SIR) guidelines.

Results

Baseline characteristics were comparable. A significantly higher proportion of patients undergoing endovascular intervention (19/21, 90.5%) achieved CR at 12 weeks, compared with those who received SMT (4/23, 17.4%; P < .01). Endovascular interventions led to greater hepatic decongestion (mean reduction in liver stiffness measurement, −16.9 kPa [95% CI, −24.9 to −8.8]) than SMT (−2.0 [95% CI, −11.8 to 7.8]; P = .02) over 12 weeks. Three patients had Grade ≥3 AE after interventions (encephalopathy [2] and transjugular intrahepatic portosystemic shunt block [1]); however, the differences in AE between the 2 groups were not statistically significant. Three deaths occurred in the SMT group within 12 weeks compared with none in the intervention group (P = .234).

Conclusions

Early endovascular interventions result in higher rates of clinical response and hepatic decongestion than SMT alone in primary BCS.

目的：本随机对照试验比较标准药物治疗（SMT）和早期血管内介入治疗作为原发性Budd-Chiari综合征（BCS）第一步治疗的临床结果。材料和方法：纳入有肝静脉阻塞（HV） [ii型]或HV合并下腔静脉阻塞[iii型]的原发性BCS症状患者。23例患者随机接受为期12周的SMT治疗，21例患者接受早期血管内介入治疗。主要终点是12周时的完全缓解（CR）：腹水消退、血清胆红素正常化、静脉曲张出血首次发作或复发的预防以及自发性细菌性腹膜炎的消失。不良事件（AE）按照介入放射学学会指南报告。结果：基线特征可比较。接受血管内介入治疗的患者在12周达到CR的比例（19/21,90.5%）明显高于SMT（4/23, 17.4%）。结论：在原发性BCS中，早期血管内介入治疗的临床缓解率和肝脏去充血率高于单纯SMT。

{"title":"Early Endovascular Intervention in Combination with Medical Therapy versus Medical Therapy Alone in the Initial Management of Patients with Primary Budd-Chiari Syndrome: A Randomized Controlled Trial","authors":"Sagnik Biswas MD, DM , Shekhar Swaroop MD, DM , Shubham Mehta MD, DM , Arnav Aggarwal MD, DM , Sarthak Saxena MD , Samagra Agarwal MD, DM , Deepak Gunjan MD, DM , Shivanand Gamanagatti MD , Shalimar MD, DM","doi":"10.1016/j.jvir.2025.107967","DOIUrl":"10.1016/j.jvir.2025.107967","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare the clinical outcomes between standard medical therapy (SMT) and early endovascular intervention as the first step of management in primary Budd-Chiari syndrome (BCS).</div></div><div><h3>Materials and Methods</h3><div>Symptomatic patients with primary BCS having either hepatic vein (HV) obstruction (Type II) or combined obstruction of HV and inferior vena cava (Type III) were enrolled. Twenty-three patients were randomized to receive SMT for 12 weeks, whereas 21 received early endovascular intervention with SMT. Primary outcome was complete response (CR) at 12 weeks: resolution of ascites, normalization of serum bilirubin, prevention of first episode of variceal bleeding or its recurrence, and absence of spontaneous bacterial peritonitis. Adverse events (AEs) were reported as per the Society of Interventional Radiology (SIR) guidelines.</div></div><div><h3>Results</h3><div>Baseline characteristics were comparable. A significantly higher proportion of patients undergoing endovascular intervention (19/21, 90.5%) achieved CR at 12 weeks, compared with those who received SMT (4/23, 17.4%; <em>P</em> < .01). Endovascular interventions led to greater hepatic decongestion (mean reduction in liver stiffness measurement, −16.9 kPa [95% CI, −24.9 to −8.8]) than SMT (−2.0 [95% CI, −11.8 to 7.8]; <em>P</em> = .02) over 12 weeks. Three patients had Grade ≥3 AE after interventions (encephalopathy [2] and transjugular intrahepatic portosystemic shunt block [1]); however, the differences in AE between the 2 groups were not statistically significant. Three deaths occurred in the SMT group within 12 weeks compared with none in the intervention group (<em>P</em> = .234).</div></div><div><h3>Conclusions</h3><div>Early endovascular interventions result in higher rates of clinical response and hepatic decongestion than SMT alone in primary BCS.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 3","pages":"Article 107967"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Effectiveness of Adrenal Cryoablation for Patients with Melanoma Metastases on Concurrent Targeted Therapy or Immunotherapy 肾上腺冷冻消融治疗黑色素瘤转移患者同步靶向治疗或免疫治疗的安全性和有效性。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-03-01 Epub Date: 2025-09-19 DOI: 10.1016/j.jvir.2025.09.022

William M. Kamp MD , Maggie X. Xiong MD , Mohammad Khavandi MD , Rahul Sheth MD , Mohamed E. Abdelsalam MD , Nariman Nezami MD , Alda Tam MD , Steven Huang MD , Peiman Habibollahi MD

引用次数: 0

Endovascular Superior Vena Cava Reconstruction for the Treatment of Symptomatic Downhill Esophageal Varices 血管内上腔静脉重建术治疗症状性下坡型食管静脉曲张。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-03-01 Epub Date: 2025-12-04 DOI: 10.1016/j.jvir.2025.107943

Jose Saucedo MD, Abhi Jairam MD, Tyler Short MD, John York MD, Christopher Ingraham MD, Jeet Minocha MD

引用次数: 0

Use of a Funneled Sheath for Embolic Protection during Deep Venous Thrombectomy 在深静脉血栓切除术中使用漏斗鞘保护栓塞。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-03-01 Epub Date: 2025-12-16 DOI: 10.1016/j.jvir.2025.107965

Antony Sare MD , Angelo G. Marino DO , Hamid Mojibian MD , Juan Carlos Perez Lozada MD , Joshua Cornman-Homonoff MD

Although treatment of deep venous thrombosis via mechanical clot removal is effective, there is a risk of intraprocedural pulmonary embolism (PE), and embolic protection provided by a recently released funneled sheath may be of value. Fifty-five procedures in which this device was used were retrospectively identified and reviewed. Device deployment was successful in all cases, and clot was apparent in the funnel at procedural conclusion in 13 (24%). Mean length of cava available for device deployment was 14.1 cm (SD ± 5.3; range, 1.8–27.6 cm). Two cases of intraprocedural PE and 1 of air embolism occurred. Use of a funneled sheath for embolic protection during mechanical thrombectomy is effective; however, appropriate techniques must be employed.

虽然通过机械去除血栓治疗深静脉血栓是有效的，但术中PE的风险和最近释放的漏斗鞘提供的栓塞保护可能是有价值的。回顾性鉴定和回顾了使用该装置的55例手术。器械部署在所有病例中都是成功的，13例（24%）在手术结束时漏斗中有明显的凝块。可用于设备部署的腔体平均长度为14.1 cm（标准偏差为5.3 cm，范围为1.8 - 27.6 cm）。术中肺栓塞2例，空气栓塞1例。在机械取栓过程中使用漏斗鞘保护栓塞是有效的，但必须采用适当的技术。

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Vascular and Interventional Radiology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀